HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases.

AbstractOBJECTIVE:
The aim of this study was to evaluate acute and long-term morbidity, recurrence rate, and overall survival in patients with multiple groin lymph node metastases treated with postoperative chemotherapy.
METHODS:
Patients affected by FIGO stages III, IVA, and IVB (pelvic lymph nodes only) submitted to surgery were then treated with four cycles of cisplatin 100 mg/m(2) given 21 days apart. Toxicity, overall, and disease-free survival were evaluated.
RESULTS:
Fourteen patients were evaluated. Median patients age was 58 (range 48-82). Median performance status was 0 (0-2). All patients completed the treatment. No treatment-related deaths occurred. Only two patients suffered from grade 4 neutropenia during chemotherapy. Three patients suffered from long-term severe lymphedema. Four patients suffered a disease recurrence. Three of these patients were subjected to surgery with no severe postoperative complications. Two of the latter patients are still alive. At a median follow-up of 57.5 months (range 23-79 months) actuarial 3-year overall survival and progression-free survival are 86% and 71%, respectively.
CONCLUSIONS:
In patients affected by vulvar cancer with multiple lymph node metastases, radical surgery followed by chemotherapy is a feasible strategy, with an acceptable short- and long-term complication rate. Results in terms of overall survival and disease-free survival are promising. Furthermore, due to absence of local long-term tissue toxicity, this strategy allows physicians to surgically treat regional lymph node recurrence safely.
AuthorsFilippo Bellati, Roberto Angioli, Natalina Manci, Marzio Angelo Zullo, Ludovico Muzii, Francesco Plotti, Stefano Basile, Pierluigi Benedetti Panici
JournalGynecologic oncology (Gynecol Oncol) Vol. 96 Issue 1 Pg. 227-31 (Jan 2005) ISSN: 0090-8258 [Print] United States
PMID15589606 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Cisplatin
Topics
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Carcinoma, Squamous Cell (drug therapy, pathology, surgery)
  • Cisplatin (adverse effects, therapeutic use)
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Humans
  • Lymph Node Excision
  • Lymph Nodes (pathology, surgery)
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Vulvar Neoplasms (drug therapy, pathology, surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: